Sancuso launches in the EU for Nausea
ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co., Ltd., announced that it has commenced the EU roll-out of its transdermal patch, Sancuso, for the prevention of Chemotherapy-Induced Nausea and Vomiting.
Sancuso has now been launched by ProStrakan�s own sales teams in the UK, Germany and the Netherlands, with additional EU countries planned for 2014. The launches follow the approval of Sancuso by the European Medicines Evaluation Agency (EMEA) in 2012. Sancuso was first launched in the US in 2008 and has been successfully marketed there by ProStrakan since then.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)